{"id":"W4387810206","doi":"10.1016/j.annonc.2023.09.2827","title":"2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Foundation Medicine; Genentech; Loxo Oncology; Astellas Pharma; Seagen; Bayer Canada; G1 Therapeutics; Sanofi; Exelixis; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Merck KGaA; Gilead Sciences; Mirati Therapeutics; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Atezolizumab; Medicine; TIGIT; Internal medicine; Oncology; Clinical trial; Phases of clinical research; Cancer; Nivolumab; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001182297,0.001422549,0.00206591,0.0002954581,0.0003009984,0.001219996,0.0006277706,0.001748265,0.0130984],"category_scores_gemma":[0.001043591,0.0005741609,0.001921154,0.0003843417,0.001030406,0.0008913879,0.0005233111,0.003802129,0.0022493],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005499811,"about_ca_system_score_gemma":0.001016632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005884845,"about_ca_topic_score_gemma":0.001997422,"domain_scores_codex":[0.9995543,0.0002607997,0.00001768775,0.00007048037,0.00001877927,0.00007788173],"domain_scores_gemma":[0.9994837,0.0001147904,0.00007721922,0.00003897124,0.00002971059,0.0002556253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.967473,0.004940751,0.0007650818,0.0006116992,0.000775569,0.00004324735,0.00004295215,0.0003902842,0.005344118,0.000190382,0.002704713,0.01671817],"study_design_scores_gemma":[0.9428713,0.05315705,0.001492554,0.00002485619,0.000275738,0.00003111778,0.00001652166,0.0002023296,0.0002923505,0.0001339956,0.001492626,0.000009617293],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9688547,0.006670923,0.001161697,0.002711221,0.001403971,0.005175006,0.005755838,0.0002602711,0.008006452],"genre_scores_gemma":[0.9685893,0.003458016,0.002310581,0.003735517,0.0006948701,0.004623733,0.006539804,0.00007844748,0.009969662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0130984,"threshold_uncertainty_score":0.04381847,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1188133651772551,"score_gpt":0.4432796996802627,"score_spread":0.3244663345030077,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}